Axcynsis Therapeutics
June 16, 2025
Company Presentation
Oncology
154
Axcynsis Therapeutics is a multi-platform antibody-drug conjugate (ADC) development company focused on creating next-generation ADC therapies incorporating a proprietary payload, AxcynDOT, designed to overcome drug resistance and address significant unmet medical needs in oncology. Headquartered in Singapore, Axcynsis leverages advanced ADC engineering and translational science to build a differentiated pipeline targeting solid tumors. The company’s lead asset has received Investigational New Drug (IND) approval from the U.S. FDA with Fast Track designation, and is expected to enter Phase 1 clinical trials in 2025. Axcynsis is committed to delivering transformative cancer therapies that improve patient outcomes globally.
Company HQ City:
Singapore
Company HQ Country:
Singapore
Year Founded:
2022
Lead Product in Development:
AT03-65 (CLDN6)
CEO
Dr Zou Bin
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
2
What is your next catalyst (value inflection) update?
June 2025
Website
www.axcynsis.com
Primary Speaker
)
)
){kind=logo}
){kind=logo}
){kind=logo}